Health Catalyst sets post-CEO role for Daniel Burton
Health Catalyst, Inc. outlines a transition arrangement with former Chief Executive Officer and principal executive officer Daniel Burton following his previously reported retirement effective February 12, 2026.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Health Catalyst, Inc. outlines a transition arrangement with former Chief Executive Officer and principal executive officer Daniel Burton following his previously reported retirement effective February 12, 2026. To support a smooth handover, Burton will remain an employee as a strategic advisor through December 31, 2026.
Under the Transition Agreement dated March 31, 2026, he will receive an average monthly base salary of $10,000 starting March 1, 2026, in exchange for continued employment. He will forfeit all unvested restricted stock units and performance-based restricted stock units that could vest after March 2, 2026, and provide a general release of claims against the company.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Monthly base salary: $10,000 per month
Retirement effective date: February 12, 2026
Transition Agreement date: March 31, 2026
+2 more
5 metrics
Monthly base salary
$10,000 per month
Average base salary beginning March 1, 2026 under Transition Agreement
Retirement effective date
February 12, 2026
Date Daniel Burton’s retirement as CEO and principal executive officer became effective
Transition Agreement date
March 31, 2026
Date the Transition Agreement between Health Catalyst and Daniel Burton was executed
Advisory role end date
December 31, 2026
Date through which Daniel Burton will serve as strategic advisor
Equity forfeiture cutoff
After March 2, 2026
Unvested RSUs and performance-based RSUs eligible to vest after this date will be forfeited
Key Terms
Transition Agreement, strategic advisor, restricted stock units, performance-based restricted stock units, +2 more
6 terms
Transition Agreement financial
"the Company and Mr. Burton entered into a transition agreement (the Transition Agreement) on March 31, 2026"
strategic advisor financial
"Mr. Burton has agreed to serve as an employee with the title of strategic advisor until December 31, 2026"
restricted stock units financial
"the forfeiture of all of his unvested restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
performance-based restricted stock units financial
"and all of his unvested performance-based restricted stock units that are otherwise eligible for vesting after March 2, 2026"
Performance-based restricted stock units are a type of employee equity award that converts into company shares only if predefined financial or operational targets are met over a set period. Think of it like a bonus check that becomes stock only when specific goals are hit; it ties pay to results, aligning managers’ incentives with shareholders. Investors care because these awards affect future share count, executive incentives, and signal how management’s success will be measured and rewarded.
general release of claims financial
"and a general release of claims against the Company"
principal executive officer financial
"from his position as Chief Executive Officer and principal executive officer of the Company"
The principal executive officer is the highest-ranking manager who leads a company’s overall strategy, operations and public communication—often acting like the captain of a ship who sets direction and makes final calls. Investors watch this person because their decisions, credibility and ability to deliver results shape company performance, risk and market confidence, and changes in that role can directly affect stock value and corporate accountability.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What leadership change did Health Catalyst (HCAT) report for Daniel Burton?
Health Catalyst reported that Daniel Burton retired as Chief Executive Officer and principal executive officer effective February 12, 2026. He will stay on as an employee in a strategic advisor role through December 31, 2026 to help ensure continuity and support the leadership transition.
What is Daniel Burton’s new role at Health Catalyst (HCAT) after retiring as CEO?
After retiring as CEO, Daniel Burton will serve as a strategic advisor to Health Catalyst until December 31, 2026. This employee role is defined in a Transition Agreement intended to enable a smooth transfer of his prior responsibilities and continued support for the company’s management team.
How much will Health Catalyst (HCAT) pay Daniel Burton under the Transition Agreement?
Under the Transition Agreement, Health Catalyst will pay Daniel Burton an average monthly base salary of $10,000 beginning March 1, 2026. This compensation is in exchange for his continued employment as strategic advisor following his retirement as Chief Executive Officer and principal executive officer.
What equity awards is Daniel Burton forfeiting at Health Catalyst (HCAT)?
Daniel Burton agreed to forfeit all of his unvested restricted stock units and all of his unvested performance-based restricted stock units that are eligible for vesting after March 2, 2026. This forfeiture is a condition of the Transition Agreement governing his post-CEO advisory role.
Does Daniel Burton provide a release of claims against Health Catalyst (HCAT)?
Yes. As part of the Transition Agreement, Daniel Burton provides a general release of claims against Health Catalyst. This type of release is common in executive transition arrangements and helps both parties clearly resolve potential employment-related claims as leadership roles change.
Where can investors find the full Transition Agreement between Health Catalyst (HCAT) and Daniel Burton?
The full Transition Agreement is filed as Exhibit 10.1 to the Form 8-K. Investors can review this exhibit for complete legal terms, detailed obligations of both parties, and any additional provisions beyond the summarized compensation, forfeiture of equity, and release of claims.
AI-generated analysis. How Rhea-AI works. Not financial advice.
